CG
ARIA

Clinton Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Clinton Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,248
Closed -$140K – 1110
2016
Q3 		$140K Buy
+10,248
New +$103K 0.01% 865

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Clinton Group's ARIA Position: Q4 2016 in Review

Clinton Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 10,248 shares — an estimated $140K sold.

Clinton Group first reported a position in ARIA in Q3 2016 and held it in 1 quarter. The position peaked at $140K in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Clinton Group reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Clinton Group sold 10,248 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $140K.
  • Clinton Group first reported a position in Ariad Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • Clinton Group's Ariad Pharmaceuticals Inc position peaked at $140K in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Clinton Group's 13F filing for Q4 2016, filed 14 Feb 2017.